Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page has removed a detailed citation of a clinical trial related to Cabozantinib and Sunitinib, which may affect the availability of important information regarding treatment options for metastatic renal cell carcinoma.SummaryDifference0.4%
- Check18 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check25 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a clinical trial for cabozantinib in non-small cell lung cancer, while adding a new version revision and a brief mention of the CRETA trial.SummaryDifference24%
- Check40 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check47 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check83 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.